- Home
- NGNE vs SI Comparison
NGNE vs SI Comparison
Compare NGNE & SI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- SI
- Stock Information
- Founded
- NGNE 2003
- SI 2009
- Country
- NGNE United States
- SI United States
- Employees
- NGNE N/A
- SI N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- SI Medical/Dental Instruments
- Sector
- NGNE Health Care
- SI Health Care
- Exchange
- NGNE Nasdaq
- SI Nasdaq
- Market Cap
- NGNE 325.3M
- SI 299.6M
- IPO Year
- NGNE N/A
- SI 2025
- Fundamental
- Price
- NGNE $19.95
- SI $14.87
- Analyst Decision
- NGNE Strong Buy
- SI Strong Buy
- Analyst Count
- NGNE 7
- SI 4
- Target Price
- NGNE $41.86
- SI $18.75
- AVG Volume (30 Days)
- NGNE 113.3K
- SI 134.7K
- Earning Date
- NGNE 08-11-2025
- SI 01-01-0001
- Dividend Yield
- NGNE N/A
- SI N/A
- EPS Growth
- NGNE N/A
- SI N/A
- EPS
- NGNE N/A
- SI N/A
- Revenue
- NGNE N/A
- SI $34,571,000.00
- Revenue This Year
- NGNE N/A
- SI N/A
- Revenue Next Year
- NGNE N/A
- SI N/A
- P/E Ratio
- NGNE N/A
- SI N/A
- Revenue Growth
- NGNE N/A
- SI 64.07
- 52 Week Low
- NGNE $6.88
- SI $11.75
- 52 Week High
- NGNE $74.49
- SI $17.94
- Technical
- Relative Strength Index (RSI)
- NGNE 48.86
- SI N/A
- Support Level
- NGNE $18.00
- SI N/A
- Resistance Level
- NGNE $19.93
- SI N/A
- Average True Range (ATR)
- NGNE 1.03
- SI 0.00
- MACD
- NGNE 0.01
- SI 0.00
- Stochastic Oscillator
- NGNE 55.71
- SI 0.00
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About SI Shoulder Innovations Inc. Common Stock
Shoulder Innovations Inc is a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market. It currently offers advanced implant systems for shoulder arthroplasty. Its products include: InSet Total Shoulder Arthroplasty; InSet Reverse Shoulder Arthroplasty; ProVoyance Shoulder Planning Software; and InSet Tray System.